SK Chemicals’ hemophilia therapy ‘AFSTYLA’ on the way to enter EU
.jpg)
On the 15th, SK Chemicals(President Man-Hoon Park) announced the hemophilia treatment ‘AFSTYLA’ was recommended by the Committee for Medicinal Products for Human Use(CHMP), an affiliated organization of the European Medicines Agency(EMA), to be approved to commercialize.
Therefore, AFSTYLA has t...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
